AARC LIVE! Virtual Learning Event — Leading Beyond Covid-19.

Tuesday, July 21 — Adult Acute Care Track

1:00 p.m.–1:40 p.m. Central

COVID-19: Observations from an Epicenter

Natalie Yip, MD

Natalie Yip

New York City (NYC) was the epicenter of the American COVID-19 pandemic. Health care workers faced unprecedented challenges as their facilities were overwhelmed with critically ill patients. Join this session to hear the firsthand experiences of a NYC-based critical care physician during the crisis. The presenter will discuss observations, lessons learned, and the rapid evolution of data that occurred during this extraordinary time.

1:45 p.m.–2:25 p.m. Central

COVID-19: The Science Behind Prone Positioning

J. Brady Scott, MSc, RRT, AE-C, FAARC, FCCP

J. Brady Scott

Placing patients with ARDS in the prone position improves oxygenation and mortality. It also appears to be an effective way to treat patient in hypoxemic respiratory failure from COVID-19. This lecture will describe the physiologic rationale and general management of patients placed in the prone position.

2:30 p.m.–3:10 p.m. Central

COVID-19: The Phenotypes and What They Mean Clinically

Neil MacIntyre, MD, FAARC

Neil MacIntyre

The primary phenotypes of COVID-19 have been described: Type L and Type H. These models generalize lung characteristics that influence the respiratory treatment for individual patients. This lecture will describe these distinct patterns and current evidence regarding how each should be managed clinically.

Sponsored by

3:15 p.m.–3:55 p.m. Central

COVID-19: Safe and Effective Delivery of Aerosolized Medications

Arzu Ari, PhD, RRT, PT, CPFT, FAARC, FCCP

Arzu Ari

During the COVID-19 pandemic there has been concern regarding staff exposure from delivering aerosolized medications to patients with the disease. This lecture will cover practical strategies to safely deliver aerosolized medications to patients with COVID-19 with mild, moderate, and severe disease.

Sponsored by

AARC CRCE logo The Adult Acute Care Track is approved for 2.68 CRCE.


Top